These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18316575)

  • 1. Evaluation of the antiangiogenic potential of AQ4N.
    O'Rourke M; Ward C; Worthington J; McKenna J; Valentine A; Robson T; Hirst DG; McKeown SR
    Clin Cancer Res; 2008 Mar; 14(5):1502-9. PubMed ID: 18316575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
    Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
    Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
    Trédan O; Garbens AB; Lalani AS; Tannock IF
    Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel function of ascorbic acid as an angiostatic factor.
    Ashino H; Shimamura M; Nakajima H; Dombou M; Kawanaka S; Oikawa T; Iwaguchi T; Kawashima S
    Angiogenesis; 2003; 6(4):259-69. PubMed ID: 15166494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
    Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
    Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
    Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
    Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
    Lu J; Chong CR; Hu X; Liu JO
    J Med Chem; 2006 Sep; 49(19):5645-8. PubMed ID: 16970390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton.
    Hayot C; Farinelle S; De Decker R; Decaestecker C; Darro F; Kiss R; Van Damme M
    Int J Oncol; 2002 Aug; 21(2):417-25. PubMed ID: 12118340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity.
    Elluru SR; Duong Van Huyen JP; Delignat S; Prost F; Heudes D; Kazatchkine MD; Friboulet A; Kaveri SV
    Anticancer Res; 2009 Aug; 29(8):2945-50. PubMed ID: 19661299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic administration of a conditionally replicating adenovirus, targeted to angiogenesis, reduced lung metastases burden in cotton rats.
    Peled M; Shaish A; Katav A; Greenberger S; Barshack I; Tal R; Bangio L; Breitbart E; Harats D
    Clin Cancer Res; 2009 Mar; 15(5):1664-73. PubMed ID: 19240175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
    Kong D; Okamura M; Yoshimi H; Yamori T
    Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular-specific quantification in an in vivo Matrigel chamber angiogenesis assay.
    Baker JH; Huxham LA; Kyle AH; Lam KK; Minchinton AI
    Microvasc Res; 2006 Mar; 71(2):69-75. PubMed ID: 16545400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia.
    Emmenegger U; Morton GC; Francia G; Shaked Y; Franco M; Weinerman A; Man S; Kerbel RS
    Cancer Res; 2006 Feb; 66(3):1664-74. PubMed ID: 16452226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
    Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
    Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
    Yakkundi A; McErlane V; Murray M; McCarthy HO; Ward C; Hughes CM; Patterson LH; Hirst DG; McKeown SR; Robson T
    Cancer Gene Ther; 2006 Jun; 13(6):598-605. PubMed ID: 16410820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues.
    Ng SS; Gütschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD
    Cancer Res; 2003 Jun; 63(12):3189-94. PubMed ID: 12810647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated inhibition of cathepsin S blocks colorectal tumor invasion and angiogenesis.
    Burden RE; Gormley JA; Jaquin TJ; Small DM; Quinn DJ; Hegarty SM; Ward C; Walker B; Johnston JA; Olwill SA; Scott CJ
    Clin Cancer Res; 2009 Oct; 15(19):6042-51. PubMed ID: 19789302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiangiogenic effects of the quinoline-3-carboxamide linomide.
    Vukanovic J; Passaniti A; Hirata T; Traystman RJ; Hartley-Asp B; Isaacs JT
    Cancer Res; 1993 Apr; 53(8):1833-7. PubMed ID: 7682157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.